10Nov

Invasive Aspergillosis Screening in COVID-19 & Critical Care Patients

IMMY sõna Aspergillus Galactomannan Lateral Flow Assay recommended by the European Confederation of Medical Microbiology (ECMM) as a screening device in ventilated patients.

 

With the emergence of COVID-19, the disease caused by the SARS-CoV-2 virus, there has been a marked increase in patients being admitted into Intensive Care Units (ICU) and particularly those requiring invasive ventilation. In light of this, new guidance has been provided by the European Confederation of Medical Microbiology (ECMM) for the diagnosis and management of patients with acute respiratory distress syndrome (ARDS) and/or ICU treatment under mechanical ventilation due to suspected pneumonia.

The ECMM specifically recommends the use of IMMY’s Aspergillus GM LFA both as part of the initial microbiological diagnostic pathway in all ICU and/or ARDS ventilation patients and also as part of a continual, tri-weekly screening program for SARS-CoV-2 and Influenza A/B positive patients.

 

Available from Alpha Laboratories, the Aspergillus GM LFA is an immunochromatographic test system for the qualitative detection of Aspergillus Galactomannan in serum and bronchoalveolar lavage (BAL) samples, providing a simple, rapid diagnosis of invasive aspergillosis, an opportunistic fungal infection caused by species of the Aspergillus genus.

 

The Aspergillus GM LFA works synergistically with other procedures such as microbiological culture, biopsy histological examination and radiographic evidence, combining to aid in the diagnosis of aspergillosis. It is easy to use, and provides high sensitivity, specificity and a rapid 30-minute test time, eliminating the need for batch testing and speeding up your results.

 

The sõna LFA Cube Reader simplifies the assessment of the intensity of the appearing lines, and is intended to be used as an aid in the interpretation of results of the Aspergillus GM LFA.

 

Please visit www.alphalabs.co.uk/af2003-r for further information on the starter pack, or contact Alpha Laboratories on 0800 38 77 32 or email marketing@alphalabs.co.uk

Related

New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes

β-lactamase enzymes inactivate β-lactam antibiotics and render them ineffective for the treatment ...

Read More >

EKF launches pocket-sized lactate monitor for sports performance monitoring at MEDICA 2018

Cardiff, UK – 22nd October 2018 – EKF Diagnostics, the global in vitro diagnostics company, announ...

Read More >

BBI Solutions Increases Capacity for Cell Culture Native Human Transferrin Production

BBI Solutions (BBI) has invested into its facilities and resource in order to increase the capacity ...

Read More >

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI Solutions (BBI) has announced the addition of over 80 new antibodies to its growing product port...

Read More >

Study confirms HORIBA POCT analyser enables earlier clinical decision-making in emergency paediatrics

Northampton, UK – 20th March 2018 – HORIBA UK Ltd, Medical announces that in a study recently unde...

Read More >

Radiometer sponsors World Sepsis Day 2017

In continuation of Radiometer’s commitment to the fight against sepsis – one of the world’s deadl...

Read More >